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Background: The c-Met receptor tyrosine kinase is aberrantly activated in many solid tumors. In a prior study we
showed that prostate cancer PC-3 cells exhibit constitutively activated c-Met without exogenous hepatocyte
growth factor (HGF); however whether this characteristic is due to an endogenous HGF/c-Met autocrine loop
remains controversial. In the current study we examined the response of PC-3 cells to an anti-HGF neutralizing
antibody or a small molecule Met kinase inhibitor (BMS-777607).
Methods: Cell scattering was tested by monitoring cell morphology after HGF stimulation. Cell migration was
examined by both “wound-healing” and transwell assasy and invasion was detected by Matrigel-coated transwell
assay. Proliferation, survival and anoikis were determined by MTT, colony formation and trypan blue exclusion assay,
respectively. Gene and protein expression were assessed by real-time PCR and Western blot, respectively.
Results: Although HGF mRNA could be detected in PC-3 cells, the molecular weight of secreted “HGF” protein was
inconsistent with the functional recombinant HGF. Furthermore, conditioned medium from PC-3 cell cultures was
ineffective at triggering either motogenic behavior or c-Met signaling in DU145, another prostate cancer cell line
expressing c-Met but lacking basal c-Met activation. PC-3 cells also were not responsive to the anti-HGF neutralizing
antibody in experiments assessing proliferation, migration, or c-Met signaling. BMS-777607 treatment with
micromolar doses nonetheless led to significant inhibition of multiple PC-3 cell functions including proliferation,
clonogenicity, migration and invasion. At the molecular level, BMS-777607 suppressed autophosphorylated c-Met
and downstream c-Src and Akt pathways.
Conclusions: These results suggest that the constitutive c-Met activation in PC-3 is independent of autocrine
stimulation. Because PC-3 cells were responsive to BMS-777607 but not the anti-HGF antibody, the findings also
indicate that under circumstances where c-Met is constitutively hyperactive in the absence of functional HGF,
targeting the c-Met receptor remains a viable therapeutic option to impede cancer progression.
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Oncogenic c-Met signaling is widely implicated in various
human malignancies. Upon binding to its ligand, hepato-
cyte growth factor (HGF), the c-Met receptor initiates a
signaling cascade leading to invasive growth and cancer
cell dissemination [1,2]. In lung cancer, expression levels
of both HGF and c-Met have been associated with
advanced tumor stage and worse clinical outcome [3]. In
prostate cancer, serum HGF has been identified as an* Correspondence: daiyao@ufl.edu
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distribution, and reproduction in any mediumindependent prognostic factor for advanced disease [4,5]
and c-Met expression in metastatic lesions frequently
exceeds that of primary tumors, with positive expression
reported in more than 90% of prostate cancer bone
metastases [6,7].
The prevalence of the activation of the HGF/c-Met in
human malignancies has driven rapid growth in drug de-
velopment to target this signaling axis for cancer therapy.
Strategies include antagonistic compounds, monoclonal
antibodies, and small molecule kinase inhibitors [8]. Neu-
tralizing antibodies targeting either HGF or c-Met have
proven capable of impairing HGF-stimulated functions inntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,





























Figure 1 Detection of HGF and c-Met in prostate cancer cells.
A, qPCR analysis of HGF and c-Met RNA levels in PC-3 and
DU145 cells. Gene expression in PC-3 cells was defined as “1”.
Columns, mean; bars, SD (n= 3). ND=not detectable. B, PC-3
cells were incubated in serum-free medium for 24 h.
Condition medium (CM) was harvested and an aliquot amount
(from 106 cells) was analyzed by Western blot under both
non-reducing and reducing conditions, with the recombinant
human HGF (10 ng/lane) as a positive control. MW=molecular
weight. kDa = kilo Dalton. Data are from 1 of 2 independent
experiments.
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ase inhibitors may have a broader range of application since
Met kinase inhibitors may be efficacious in cancers driven
by both HGF [11] and c-Met [12]. One leading candidate is
ARQ197, a Met inhibitor that has shown activities in pre-
clinical models and proves partial responses in patients with
metastatic diseases [13]. BMS-777607 is another potent
Met kinase inhibitor that entered clinical evaluation. Pre-
clinical studies have shown that BMS-777607 delays the
growth of human gastric cancer xenografts with MET
gene amplification [14], inhibits HGF-induced metastasis-
related functions in prostate cancer cells [15], and impairs
pulmonary metastases in a rodent sarcoma model with
hyperactivated c-Met [16]. These observations imply that
BMS-777607 treatment may result in anti-proliferative and
anti-metastatic effects in cancers with aberrant c-Met ac-
tivity irrespective of the involvement of HGF.
Abnormal c-Met activation as a result of gene amplifi-
cation, mutation, or transactivation can occur in certain
cancer types [2]. However, c-Met overexpression due to
upregulation at the transcriptional level remains the
predominant event for the majority of human malignan-
cies [17]. In this scenario, activation of the c-Met receptor
still depends on the HGF ligand, however increased
expression of c-Met on the cell surface could favor HGF-
independent activation through spontaneous receptor
dimerization [18]. In some cases, tumor cells express both
HGF and c-Met, thus potentially establishing an autocrine
loop in which the secreted HGF ligand by tumor cells
binds to the c-Met receptor and causes its activation.
Such HGF-dependent autocrine c-Met activation, consid-
ered a self-supportive mechanism for cell transformation,
proliferation and survival, has been detected in various
human primary and metastatic tumors, including breast
cancer [19], glioma [20] and osteosarcoma [21].
Although prostate cancer PC-3 cells are responsive to
exogenous HGF [15,22], our previous study showed that
these cells exhibit a high basal level of autophosphorylated
c-Met, suggesting that c-Met could be constitutively acti-
vated even in the absence of exogenous HGF [15]. How-
ever, whether such constitutive c-Met activation occurs in
an autocrine manner is controversial. Some studies suggest
the existence of an HGF/c-Met autocrine loop [18,23],
whereas others indicate that PC-3 cells do not express HGF
[24,25]. The current study examines the expression and
function of HGF produced by PC-3 cells and the response
of these cells to an anti-HGF neutralizing antibody or
the small molecule Met kinase inhibitor, BMS-777607.
Results
HGF mRNA could be detected in PC-3 however secreted
“HGF” is not consistent with the purified HGF protein
We first tested the gene expression of both the HGF
ligand and c-Met receptor in PC-3 and DU145 cells.HGF mRNA could be detected in PC-3 (CT ~31.8) but
not DU145 cells (CT >37.0) (Figure 1A). In accordance
with other studies [24], MET gene expression in PC-3
was higher than DU145 (Figure 1A, 7.1-fold). We next
tested whether PC-3 cells secreted HGF protein by ana-
lyzing the CM. Mature HGF (~70-80 kDa) should con-
tain a disulfide bond that can be cleaved in the presence
of a reducing agent to generate an α (~ 60 kDa) and a β
(~ 30 kDa) subunit [26]. As shown in Figure 1B,
although the anti-HGF (α subunit) antibody could detect
clear bands in the CM of PC-3 cells, the molecular
weight of these bands did not match that of the α
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and 60 kDa under non-reducing and reducing condi-
tions, respectively).
CM of PC-3 was not functional
To determine whether the released “HGF” possessed
biological function, serum-starved DU145 cells were
incubated with CM from PC-3 cells. DU145 cells were
used because these prostate cancer cells do not phos-
phorylate c-Met without exogenous HGF [27]. Unlike
pure HGF, CM from PC-3 cells could not induce either
scattering or migration in DU145 cells (Figure 2A). Fur-
thermore, CM without serum (0% FBS) failed to induce
phosphorylation of c-Met in the catalytic residues
(Y1234/1235) and downstream molecules ERK (T202/
Y204) and Akt (S473), which could be achieved by add-
ing pure HGF (Figure 2B). To rule out the possibility
that the secreted “HGF” may be inactivated in the ab-
sence of serum [28], CM with 10% FBS was tested. The
results showed that c-Met was not phosphorylated by
serum-containing CM (Figure 2B).
PC-3 was not responsive to the anti-HGF
neutralizing antibody
The results of Figure 2 shown that CM from PC-3 cells
cannot activate c-Met in DU145 cells; a cell line which
does not express the HGF ligand but has the c-Met re-
ceptor (Figure 1A). To explore the functional effect of
the secreted “HGF” on PC-3 cells themselves, cells were
incubated with 10 μg/ml of an anti-HGF neutralizing
















Figure 2 Effect of anti-HGF neutralizing antibody on PC-3 cell functio
were incubated with CM (serum-free) from 106 PC-3 cells or HGF (5 ng/ml)
respectively. Magnification, ×5. Data are from 1 of 3 independent experime
PC-3 cells) in the absence (0%, lane 2) or presence of FBS (10%, lane 7), or
15 min, with untreated controls in a fresh medium with 0% (lane 1) or 10%
cells were pre-treated with anti-HGF neutralizing antibody (anti-HGF, lane 4
medium at 37°C for 2 h, to confirm whether c-Met activation if could be tr
c-Met signaling molecules were analyzed by Western blot, with total c-Metsufficient to neutralize HGF [9], did not reduce PC-3 cell
proliferation (Figure 3A), colony formation (Figure 3B)
or migration (Figure 3C), as compared to nIgG.
Anti-HGF neutralizing antibody did not block constitutive
c-Met signaling in PC-3
To confirm that the anti-HGF antibody could block the
c-Met pathway, PC-3 cells were incubated with the anti-
HGF antibody under various conditions. Although phos-
phorylated c-Met and downstream targets such as Akt
and ERK were suppressed by the anti-HGF antibody in a
dose-dependent fashion in the presence of exogenous
HGF, in the absence of HGF, these signaling molecules
were not eliminated by the anti-HGF antibody as com-
pared to nIgG (Figure 4A). Prolonged (24 h) treatment of
the anti-HGF antibody also failed to decrease the basal
level of p-c-Met and p-Akt in serum-deprived PC-3 cells
(Figure 4B). To further exclude the possibility that the
“HGF” that had been secreted before serum starvation
could have bound the c-Met receptor and triggered con-
stitutive c-Met phosphorylation, PC-3 cells were quickly
rinsed with a wash buffer to strip any potential pre-exist-
ing “HGF” molecules on the cell surface [29]. The results
showed that even after the rinse, the expression of p-c-
Met and p-Akt still remained unchanged (Figure 4C).
PC-3 was responsive to the small molecule Met kinase
inhibitor BMS-777607
To test whether a small molecule Met kinase inhibitor
could impair critical Met associated cell functions, PC-3
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ns. A, Serum-starved DU145 cell colonies and scratched monolayers
for 24 h, for the assessment of cell scattering and migration,
nts. B, serum-starved DU145 cells were incubated with CM (from 106
pure exogenous HGF in a fresh FBS-free medium (5 ng/ml, lane 5) for
FBS (lane 6) accordingly. In the CM with 0% FBS (lanes 2–4), DU145
) or normal mouse IgG1 control (nIgG, lane 3) in a fresh serum-free
iggered by the CM can be blocked by the neutralizing antibody.












































Figure 3 Effect of anti-HGF neutralizing antibody on PC-3 cell
functions. PC-3 cells were treated with 10 μg/ml of the neutralizing
antibody (anti-HGF) or control antibody (nIgG) for 4 days (A),
14 days (B) or 1 day (C), for the detection of cell growth (MTT assay,
A), clonogenicity (colony formation assay, B), or cell migration
[“wound-healing” assay, C (magnification, ×5)]. Columns, mean; bars,
SD (n= 6). Data represent ≥3 independent experiments.
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bition at 10 μM) and clonogenicity (Figure 5B, 38.2±9.9%
inhibition at 3 μM) were found to be impaired by BMS-
777607 with doses greater than 1 μM. However, apoptosis
was not observed even with the highest drug concentra-
tion (data not shown). Migration assessed using a
“wound-healing” assay showed that this agent reduced the
number of cells moving into the denuded area at concen-
trations ≥1 μM. Moreover, in the transwell-assays, both
cell migration (Figure 5D) and invasion (Figure 5E) werefound to be significantly inhibited by BMS-777607 at
1 μM (P< 0.05).
Anoikis is a mode of anchorage-independent cell death
that negatively affects cancer cell dissemination and
anoikis-resistance is considered as a critical player in
prostate cancer metastasis [30-32]. To test whether Met
inhibition will lead to anoikis, suspended PC-3 cells were
incubated with BMS-777607 or wortmannin (an irre-
versible PI3K inhibitor) for 3 days. While wortmannin
significantly increased anchorage-independent cell death
(P< 0.001), BMS-777607 did not significantly affect
anoikis even at the highest dose tested (10 μM, P= 0.13)
(Figure 5F).
BMS-777607 blocked constitutive c-Met signaling in
PC-3 cells
To investigate signaling alterations after c-Met kinase
inhibition, cells were exposed to BMS-777607 for vari-
ous doses and times. BMS-777607 completely eliminated
c-Met autophosphorylation at doses as low as 0.1 μM
(Figure 6A). While p-Akt was modestly inhibited by
BMS-777607 at the highest dose (10 μM), expression
levels of autophosphorylated Src (Y416) and Src-
dependent phosphorylated FAK (Y861) were decreased
with doses greater than 0.5 μM (Figure 6A). In contrast,
autophosphorylated FAK (Y397) was not affected by
BMS-777607 (Figure 6A). When cells were treated with
BMS-777607 for prolonged periods (24 h), phosphoryl-
ation of c-Met, c-Src and FAK (Y861) remained inhibited.
Furthermore, phosphorylation of Akt and mammalian tar-
get of rapamycin (mTOR) as well as downstream mole-
cules S6K (T389) and S6 (S234/235) started to be ablated
at 3~ 24 h after drug treatment (Figure 6B). ERK phos-
phorylation however, showed little change by either high
dose or long term treatment (data not shown).
Discussion
MET oncogene overexpression has been described in a
variety of human cancers including prostate [7]. Aber-
rant c-Met activation has been shown to be strongly
involved in prostate cancer aggressiveness and poorly
clinical outcome [2,6,7]. In the current study human
metastatic prostate cancer PC-3 cells were found to
overexpress not only c-Met but also HGF at the tran-
scriptional level (Figure 1A). Since a high basal level of
phosphorylated c-Met is also observed in PC-3 cells, it
was anticipated that an HGF/c-Met autocrine loop that
induces constitutive c-Met activation exist in this cell line.
However, the molecular weight of the secreted “HGF” by
PC-3 cells was inconsistent with the recombinant HGF
protein (Figure 1B). Furthermore, c-Met-associated func-
tions were not activated by CM from PC-3 cells (Figure 2),
suggesting that what was secreted by these cells was












































































Figure 4 Effect of anti-HGF neutralizing antibody on c-Met signaling in PC-3 cells. A, PC-3 cells were serum-starved overnight and treated
with the anti-HGF neutralizing antibody (anti-HGF) or control antibody (nIgG) for 2 h before stimulation with or without HGF (25 ng/ml) for
15 min. B, PC-3 cells were serum-starved over night and continuously treated with anti-HGF or nIgG for 24 h. C, PC-3 cells were serum-starved
overnight and rinsed twice in a wash-out buffer (serum-free medium with 0.5 M NaCl, pH 3.7) for 30 s. Whole cell lysates were harvested
immediately followed by Western blot analysis. Actin (A, B) or total c-Met (C) was used as a loading control.
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not respond to the anti-HGF neutralizing antibody
(Figures 3 and 4); a finding that supports the conclu-
sion that the constitutive c-Met activity in PC-3 cells is
autocrine-independent.
Two questions arise from the results of the current
study. Firstly, what is the “HGF” produced by PC-3 cells
and what is its function? Mature HGF/SF is composed
of an α-chain (69 kDa) and a β-chain (34 kDa) that are
linked to form a heterodimer [33]. Since the primers
are designed to probe the α subunit of HGF mRNA
(Figure 1A) and a single band (~ 45 kDa) can be
detected under non-reducing conditions (Figure 1B, left),
the secreted protein might be an isoform of HGF [34].
Secondly, if an autocrine loop is not involved, then what
accounts for the constitutive c-Met activation? To date
MET gene abnormalities such as activating mutations or
amplifications have not been reported in PC-3 cells nor
prostate cancer in general [2], suggesting alterations at
the genetic level may not be involved. Since c-Met pro-
tein overexpression due to mRNA upregulation occurs
predominantly in human cancers [17], the basal level of
phosphorylated c-Met in PC-3 cells may simply be a re-
sult of increased MET transcripts via unknown mechan-
isms. In addition, the cross-talk between c-Met and
other signaling molecules post-transcriptionally could be
a possibility given that c-Met is able to be transactivated
by several other transmembrane proteins [35]. In the
PC-3 cell line, basal c-Met phosphorylation remained
unaffected by exposure to either gefitinib or dasatinib
(data not shown), suggesting that c-Met is not activatedby epidermal growth factor receptor (EGFR) or c-Src,
two kinases shown to be involved in c-Met transactiva-
tion in some studies [36,37]. However other signaling
molecules such as Ron, another Met receptor family
member which is also overexpressed in PC-3 cells [38],
might transactivate c-Met. Finally, an HGF-mediated
“intracellular” autocrine mechanism [25], although rare,
could be another possibility.
Despite the unresponsiveness of PC-3 cells to anti-
HGF antibody, the Met kinase inhibitor BMS-777607
did significantly inhibit PC-3 cell proliferation, clo-
nogenicity, migration and invasion (Figure 5) as well as
c-Met signaling pathways (Figure 6). Coupled with our
previous findings [15], these results suggest that in the
PC-3 tumor model, c-Met signaling plays a major role in
the metastasis-related behavior irrespective of the HGF
status. Consistent with the impact on cellular functions,
BMS-777607 also significantly ablated molecular c-Met
activity and downstream pathways including c-Src/FAK
and Akt-mTOR, indicating that c-Src and Akt are two
mediators of constitutive c-Met signaling. Interestingly,
exogenous HGF cannot phosphorylate c-Src in PC-3
cells, suggesting that c-Src does not mediate HGF-
induced c-Met activation [15]. The discrepant role of
c-Src in c-Met-mediated molecular events reveals the
complex interplay between these signaling components.
PC-3 cells were originally isolated from a prostate
cancer bone metastasis [39]. Since HGF is enriched in
the stroma of both the prostatic gland [40] and bone
marrow [41] and is considered to be sufficient to trigger








































































































Figure 5 Effect of Met inhibitor BMS-777607 on PC-3 cell functions. PC-3 cells were treated with indicated doses of BMS-777607 for 4 days
(A), 14 days (B), 1 day (C), 2 days (D, E) and 3 days (F), for the detection of cell growth (MTT assay, A), clonogenicity (colony formation assay, B),
cell motility [“wound-healing” assay, C (magnification, ×5)], migration (transwell assay, D), invasion (transwell assay, E) and anoikis (trypan blue
exclusion assay, F), respectively. Data either represent 1 of 3 independent experiments (B, C) or are from> 3 independent experiments (A, D, E, F).
A, B, F: Columns, mean; bars, SD (n≥9). D, E: boxes, median (middle line) with 75th (upper boundary) and 25th (lower boundary) percentiles; whiskers,
90th (upper) and 10th (lower) percentiles (n= 8). *, P< 0.05 (t-test in A and Wilcoxon test in D, E); ***, P< 0.001 (t-test in A, B, F).
Wort =Wortmannin.
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to survive and metastasize in a scenario where exogen-
ous HGF is lacking. Anchorage independence is sug-
gested as a factor in the survival of circulating tumor
cells [42], but our data indicate that c-Met is not essen-
tial for maintaining anchorage-independent cell survival
(Figure 5F). Thus while targeting c-Met kinase is un-
likely to reduce viability of non-adherent tumor cells,
small molecule Met kinase inhibitors may have signifi-
cant therapeutic potential as agents that interfere with
the metastatic phenotypes associated with c-Met.
Conclusions
In summary, the current study showed that the Met
kinase inhibitor BMS-777607, but not the anti-HGFneutralizing antibody, exerted suppressing effects on
c-Met-associated cellular functions in PC-3 cells that
express constitutively activated c-Met. These findings
suggest the possibility that in cancers where hyperactive
c-Met is independent of HGF-mediated autocrine stimu-
lation, targeting the Met receptor may be more effective




BMS-777607 was kindly provided by Dr. Joseph Fargnoli
(Bristol-Myers Squibb, Piscataway, NJ). The powder was
dissolved in dimethyl sulfoxide (DMSO) and stored at
−20°C. Recombinant human HGF, anti-HGF neutralizing






















Figure 6 Effect of BMS-777607 on c-Met signaling in PC-3 cells. PC-3 cells were treated with indicated doses of BMS-777607 for 1 h (A) or
with BMS-777607 (1 μM) for indicated times (B). Whole cell lysates were harvested and analyzed by Western blot, with actin as a loading control.
Data represent 1 of 2 independent experiments.
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purchased from R&D Systems (Minneapolis, MN).
Wortmannin was obtained from Calbiochem (Gibbs-
town, NJ). Additional chemicals were purchased from
Sigma (St. Louis, MO) unless otherwise indicated. The
following primary antibodies were used: phospho-c-Met
(Y1234/1235), total c-Met, phospho-Akt (S473), phos-
pho- extracellular signal-regulated kinases (ERK, T202/
Y204), phospho-c-Src (Y416), phospho-focal adhesion
kinase (FAK, Y861), phospho-S6 kinase (S6K, T389) and
phospho-S6 (S234/235) (Cell Signaling, Danvers, MA);
phospho-FAK (Y397) (Chemicon, Billerica, MA); β-actin
(Sigma); HGF (only recognizes α subunit of the HGF
protein, Santa Cruz, Santa Cruz, CA).
Cell culture
Human prostate cancer cell lines PC-3 and DU145 were
obtained from the American Type Culture Collection.
PC-3 and DU145 cells were maintained in Ham’s F-12 K
and DMEM respectively, supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml
streptomycin. Cells were cultured in a 5% CO2 humidi-
fied incubator at 37°C. All experiments were performed
using cells in 10 passages.
Conditioned medium (CM)
Subconfluent PC-3 cells were incubated with complete
or serum-free medium for 24 h. The supernatant was
collected and spun down at 2,500 rpm for 10 min to
remove any intact cells or cell debris. CM was further
concentrated by centrifuging at 2,000 × g for 20 min
using an Amicon Ultra Centrifugal filter device (cut-off
molecular weight 10 kDa, Millipore). CM from 106 cellswas analyzed by Western blot on a 10% SDS-polyacryl-
amide gel under both reducing (with β-mercaptoethanol)
and non-reducing (without β-mercaptoethanol) conditions
to detect secreted HGF. In some circumstances, CM was
directly used for the experiments without concentration.
Cell scattering
Cells were seeded in a 6-well plate (103 cells/well) and
cultured for 7 days until colonies formed. Cell colonies
were incubated with serum-free medium overnight and
challenged with either CM or pure HGF (5 ng/ml). Cells
were stained with crystal violet (0.1%) 24 h after treat-
ment. Scattered colonies were photographed.
Cell proliferation
Cells were seeded in a 96-well plate at a density of
5 × 103 cells/well and exposed to desired agents for a
period of 96 h. At the end of the treatment period cells
were incubated with WST-8 (MTT assay reagent) in a
Cell Counting Kit (Dojindo Molecular Technologies,
Rockville, MD) according to the manufacturer’s instruc-
tion. Absorbance was determined at 450 nm colorimetri-
cally. Cell proliferation (%) was calculated as the ratio of
the absorbance from treated samples compared to that
of the untreated control sample.
Colony formation
Cells were seeded into a 6-well plate and continuously
exposed to desired agents for 14 days. Plates were
stained with crystal violet and cell colonies (> 50 cells)
were counted. Plating efficiency was calculated as
the percentage of seeded tumor cells forming macro-
scopic colonies.
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Cell migration was determined using both “wound-
healing” and transwell assays. For the “wound-healing”
assay, cells were seeded in a 6-well plate and grown for
48 h to allow them to reach confluency. Prior to the
treatment, a 2 mm wide scratch was made in the mono-
layer using a sterilized 1 ml pipette tip. Cell migration
was assessed 24 h after treatment. For the transwell
assay, cells (104/insert) were seeded into a commercial
transwell insert (8 μm pore membrane) and incubated
with desired agents. Migrated cells on the bottom of the
filter were stained and counted under a light microscope
24 h after treatment.
Cell invasion
Invasive ability of cells was tested using a transwell
insert pre-loaded with Matrigel (BD Biosciences, San
Diego, CA). Inserts were incubated with serum-free
medium at 37°C for 2 h to allow rehydration of Matrigel.
Agents to be tested were added into both upper and
lower chambers at equal concentrations. Cells suspended
in serum-free medium were then loaded onto the top
chamber (104/insert). Complete medium was used in the
lower chamber as a chemo-attractant. After 24 h of
incubation, the Matrigel was removed and the inserts
were stained with crystal violet. Invaded cells on the
underside of the filter were counted.
Anoikis
Cells were seeded into a 6-well plate coated with poly-
HEMA (2-hydroxyethyl methacrylate, 2 mg/100 μl/cm2)
at a density of 105/well and continuously incubated with
the compounds for 72 h. The suspended cells were har-
vested and incubated with trypsin-EDTA (0.05%) at 37°C
for 20 min to dissociate cell clumps. Single cell suspen-
sions were stained with the trypan blue and cells were
counted using a hemocytometer. Cell death (%) was cal-
culated from the ratio of positive-stained to total cells.
Western blot
Cells were harvested and disrupted in a radioimmuno-
precipitation assay (RIPA) lysis buffer buffer (50 mM
Tris–HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40,
0.25% sodium deoxycholate and 1 mM EDTA with pro-
tease inhibitor cocktail, 1 mM NaF and 1 mM Na3VO4).
Equal amounts of whole cell lysates were resolved by
SDS-PAGE (Bio-Rad), electrotransferred to a nitrocellu-
lose membrane (Bio-Rad), probed with relevant primary
antibodies at 4°C overnight, incubated with horseradish
peroxidase (HRP) conjugated secondary antibodies
(Jackson ImmunoResearch, West Grove, PA) and
detected with an enhanced chemiluminescence substrate
(Amersham, Piscataway, NJ).Quantitative real time PCR (qPCR)
qPCR was performed as described previously [43].
Briefly, total RNA was extracted using TRIzol (Invitro-
gen) and reverse transcription was conducted following
the instructions of the TaqMan Reverse Transcription
Kit (Applied Biosystems, Foster City, CA). For qPCR,
1 μl gene primers with SYBR Green PCR Master Mix
(Applied Biosystems) in 20 μl reaction volume was
performed. Primers were designed as: HGF, forward,
5′-CTCACACCCGCTGGGAGTAC-3′, reverse, 5′-TCC-
TTGACCTTGGATGCATTC-3′; c-Met, forward, 5′-CT-
GCCTGCAATCTACAAGGT-3′, reverse, 5′-ATGGTCA-
GCCTTGTCCCTC-3′; actin (an internal control): for-
ward, 5′-CTCCTCCTGAGCGCAAGTACTC-3′, reverse,
5′-TCCTGCTTGCTGATCCACATC-3′. All reactions
were performed on the ABI7500 Fast Real-Time PCR
System (Applied Biosystems). mRNA levels of tested
genes were normalized to Actin according to the follow-
ing formula: 2^ –(CT test – CT Actin), where CT is the
threshold cycle. Fold of gene expression of PC-3 cells was
defined as “1”.
Statistical analysis
Two-tailed Student’s t-test (parametric) or Wilcoxon rank
sum test (non-parametric) were employed for data anal-
ysis by GraphPad Prism 5.0 (San Diego, CA). A threshold
of P< 0.05 was defined as statistically significant.
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